Besides, the survival data revealed that the patients within IIIa stages who carried high level of HACE1 exhibited a better prognosis, from which we assumed that HACE1 was beneficial for patients in early stage and blocking the abnormal down‐regulation of HACE1 in early stage might give an inspiration to enhance the treatment of patients with gastric cancer. The gene discussed is HACE1; the disease is gastric cancer.